ACCESS Newswire
12 Dec 2019, 22:01 GMT+10
HOUSTON, TX / ACCESSWIRE / December 12, 2019 / SpinalCyte, LLC, a Texas-based regenerative medicine company, is proud to have Chief Executive Officer, Pete O'Heeron named one of the 30 Best CEOs of 2020 by Silicon Review magazine. His in-depth profile interview can be found here: https://thesiliconreview.com/magazine/profile/pete-o-heeron-ceo-through-continued-discovery-and-development-in-the-lab/
In part, the interview delves into SpinalCyte discoveries using human dermal fibroblasts to regenerate tissue. Mr. O'Heeron leads a scientific team which is pursuing a cure for degenerative disc disease along with multiple sclerosis, chronic traumatic encephalopathy (CTE) and other disease pathways using its first product offering, CybroCell. SpinalCyte's current intellectual property portfolio now includes 174 U.S. and international patents issued and/or pending which are focused on the clinical use of fibroblasts.
'To be honored with a Top 3 spot on this list is a credit to the work of our scientists and the breakthroughs they are developing in the lab', commented Pete O'Heeron. 'Our work with fibroblasts is beginning to gain the attention of the medical community and this honor will highlight the work of our team.'
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient's spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
About CybroCell
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte's Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal replacement using human dermal fibroblasts. Currently, SpinalCyte holds 60 U.S. and international issued patents and has filed for an additional 110+ patents pending and issued across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.
Contact:
Clinical Contact: [email protected]
SOURCE: SpinalCyte, LLC
Get a daily dose of California Telegraph news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to California Telegraph.
More InformationWASHINGTON, D.C.: President Donald Trump will meet Israeli Prime Minister Benjamin Netanyahu at the White House on Monday. President...
GENEVA, Switzerland: A new United Nations report alleges that dozens of global corporations are profiting from and helping sustain...
LONDON, UK - Lawmakers in the United Kingdom have voted overwhelmingly to proscribe the direct-action group Palestine Action as a terrorist...
DHARAMSHALA, India: The Dalai Lama is set to address a significant three-day conference of Buddhist leaders this week, coinciding with...
WASHINGTON, D.C.: In a significant ruling last week, the U.S. Supreme Court upheld a Texas law requiring age verification for users...
ISTANBUL/PARIS/BRUSSELS: As searing temperatures blanket much of Europe, wildfires are erupting and evacuation orders are being issued...
SAN FRANCISCO, California: Grammarly is doubling down on AI-powered productivity tools with the acquisition of Superhuman, a sleek...
NEW YORK, New York -U.S. stock markets closed with broad gains on Thursday, led by strong performances in U.S. tech stocks, while European...
LONDON/STOCKHOLM: The Persson family is ramping up its investment in the H&M fashion empire, fueling renewed speculation about a potential...
PARIS, France: L'Oréal is making a fresh play in the booming premium haircare segment with a new acquisition. The French beauty conglomerate...
MENLO PARK, California: Robinhood is giving European investors a new way to tap into America's most prominent tech names — without...
NEW YORK, New York - U.S. stocks diverged on Wednesday for the second day in a row. The Standard and Poor's 500 hit a new all-time...